Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Announcing the $256 million deal, the New York-based biotech firm vowed to comply with 23andMe’s privacy policy, which was a ...

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

A biotech company has announced plans to acquire 23andMe after the genetic testing company filed for Chapter 11 bankruptcy.

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

A Philadelphia entrepreneur developing eye repair tech stood out among international contenders as it gears up to raise a ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...